If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 21 - 30 of 294
A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
A Study of TNB-486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Protocol No
TENEOBIO-TENEOTWO-TNB486-001
A Phase 1, Open-label, Study of Voruciclib in Subjects with Relapsed and/or Refractory B-cell Malignancies or Acute Myeloid Leukemia After Failure of Prior Standard Therapies and Voruciclib in Combination with Venetoclax in Subjects with Relapsed and
This project is being done to determine the highest safely tolerated dose of voruciclib in patients that have relapsed and/or refractory B cell type cancers or acute myeloid leukemia.
Protocol No
MEI-ME-522-001
A Multi-arm Phase 1b Study of Talquetamab with Other Anticancer Therapies in Participants with Multiple Myeloma
To characterize the safety and tolerability of talquetamab when administered in different combination regimens.
Protocol No
JANSSEN-JNJ-64407564-MONTAL-2
A Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 Administered as Monotherapy or in Combination with Nivolumab or Standard of Care in Patients with Locally Advanced or Metastatic Solid Tumors
This project is being done to find out the highest tolerable dose of TST001 that can be given to patients when given via IV once every 2 or 3 weeks, what are the side effects, how much TST001 is in the blood at a specific times after dosing and how does the body get rid of it.
Protocol No
MABSPACE-TST001-1001
Categories
Cancer,
Cervix,
Early Phase/Multiple Disease Site Cancers,
Thoracic Cancers,
Sarcoma,
Skin Cancers,
Prostate and Urologic Cancers,
Head and Neck Cancers,
Gynecologic Cancers,
Gastrointestinal Cancers,
Eye/Orbital Cancers,
Endocrine Cancers,
Breast Cancers,
Lung,
Esophagus,
Other Skin,
Melanoma, Skin,
Other Urologic,
Bladder,
Prostate,
Kidney,
Lip, Oral Cavity and Pharynx,
Larynx,
Other Gynecologic,
Uterine,
Ovary
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma
Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma
Protocol No
NRG-GY026
Categories
A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
Protocol No
NRG-BN012
Categories
Cancer,
Colorectal,
Early Phase/Multiple Disease Site Cancers,
Thoracic Cancers,
Sarcoma,
Skin Cancers,
Prostate and Urologic Cancers,
Head and Neck Cancers,
Gynecologic Cancers,
Gastrointestinal Cancers,
Endocrine Cancers,
Breast Cancers,
Lung,
Esophagus,
Melanoma, Skin,
Bladder,
Prostate,
Kidney,
Lip, Oral Cavity and Pharynx,
Larynx,
Uterine,
Ovary,
Cervix,
Stomach,
Pancreas/Liver,
Esophagus
Phase 1 Study of Redirected Autologous T Cells Engineered to Contain an Anti-CD19 and Anti-CD20 scFv Coupled to CD3 and 4-1BB Signaling Domains in Patients with Relapsed and/or Refractory CD19 or CD20 B-Cell Acute Lymphoblastic Leukemia
Phase 1 Study of CAR-20/19-T Cells in Pediatric and Young adult Patients with R/R B Cell ALL
Protocol No
IIT-TALANO-CART-ALL
Categories
A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients with Phlebotomy Dependent Polycythemia Vera (PD-PV)
A Study to Evaluate Sapablursen in Patients With Polycythemia Vera
Protocol No
IONIS-ISIS-702843-CS4-PV
Categories
Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS with Brain Metastasis Velocity >/= 4 Brain Metastases/Year
Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
Protocol No
NRG-BN009
Categories
Cancer,
Colorectal,
Early Phase/Multiple Disease Site Cancers,
Thoracic Cancers,
Sarcoma,
Skin Cancers,
Prostate and Urologic Cancers,
Head and Neck Cancers,
Gynecologic Cancers,
Gastrointestinal Cancers,
Endocrine Cancers,
Breast Cancers,
Lung,
Esophagus,
Melanoma, Skin,
Bladder,
Prostate,
Kidney,
Lip, Oral Cavity and Pharynx,
Larynx,
Uterine,
Ovary,
Cervix,
Stomach,
Pancreas/Liver,
Esophagus
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score
Protocol No
NRG-GU010-GUIDANCE
Categories